Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18990401 | COMPOSITION FOR REGULATING PRODUCTION OF PROTEINS | December 2024 | March 2025 | Allow | 3 | 0 | 0 | No | No |
| 18926867 | STERILE HUMAN PLACENTAL ALLOGRAFTS HAVING A PLURALITY OF SLITS, OPENINGS, AND/OR FENESTRATIONS FORMED THEREON | October 2024 | March 2025 | Allow | 5 | 1 | 1 | Yes | No |
| 18824576 | DIFFERENTIATION OF PANCREATIC ENDOCRINE CELLS | September 2024 | June 2025 | Allow | 9 | 3 | 0 | Yes | No |
| 18824588 | DIFFERENTIATION OF PANCREATIC ENDOCRINE CELLS | September 2024 | December 2024 | Allow | 4 | 2 | 0 | No | No |
| 18797392 | IONIZABLE CATIONIC LIPIDS | August 2024 | February 2025 | Allow | 7 | 1 | 0 | No | No |
| 18752372 | METHOD FOR SIMPLY CONSTRUCTING TWO-COMPONENT VIRAL VECTOR AND RELATED APPLICATIONS THEREOF | June 2024 | June 2025 | Allow | 11 | 1 | 1 | No | No |
| 18672959 | TAURINE SUPPLEMENTED CELL CULTURE MEDIUM AND METHODS OF USE | May 2024 | March 2025 | Allow | 9 | 2 | 0 | No | No |
| 18672979 | TAURINE SUPPLEMENTED CELL CULTURE MEDIUM AND METHODS OF USE | May 2024 | March 2025 | Allow | 9 | 2 | 0 | No | No |
| 18617912 | CD19 AND CD22 CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | March 2024 | February 2025 | Allow | 11 | 1 | 0 | Yes | No |
| 18591883 | STERILE HUMAN PLACENTAL ALLOGRAFTS HAVING A PLURALITY OF SLITS, OPENINGS, AND/OR FENESTRATIONS FORMED THEREON | February 2024 | September 2024 | Allow | 7 | 1 | 1 | Yes | No |
| 18582361 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | February 2024 | August 2024 | Allow | 6 | 1 | 0 | No | No |
| 18682853 | HIGH-THROUGHPUT PRECISION GENOME EDITING IN HUMAN CELLS | February 2024 | May 2025 | Abandon | 16 | 2 | 0 | No | No |
| 18433467 | TRADITIONAL CHINESE MEDICINE MIXTURE AND TRADITIONAL CHINESE MEDICINE EFFECTIVE INGREDIENT COMPOUND WITH FUNCTION OF PROMOTING DIRECTIONAL DIFFERENTIATION OF STEM CELLS INTO CARDIOMYOCYTES, AND APPLICATIONS THEREOF | February 2024 | October 2024 | Allow | 9 | 2 | 0 | No | No |
| 18431504 | POLYNUCLEOTIDE COMPOSITIONS, RELATED FORMULATIONS, AND METHODS OF USE THEREOF | February 2024 | September 2024 | Allow | 8 | 1 | 0 | Yes | No |
| 18411647 | TRANSGENE CASSETTES DESIGNED TO EXPRESS A HUMAN MECP2 GENE | January 2024 | March 2025 | Allow | 14 | 1 | 0 | No | No |
| 18397091 | COMPOSITIONS AND METHODS FOR IN UTERO DELIVERY | December 2023 | September 2024 | Allow | 8 | 2 | 0 | Yes | No |
| 18394522 | HARVESTING CELL-BASED MEAT | December 2023 | March 2024 | Allow | 3 | 1 | 0 | No | No |
| 18391799 | DIFFERENTIATION OF PANCREATIC ENDOCRINE CELLS | December 2023 | April 2024 | Allow | 4 | 1 | 0 | No | No |
| 18391867 | RE-AGGREGATION OF STEM CELL-DERIVED PANCREATIC BETA CELLS | December 2023 | January 2025 | Abandon | 13 | 1 | 0 | No | No |
| 18540309 | TARGETED GENE INSERTION FOR IMPROVED IMMUNE CELLS THERAPY | December 2023 | April 2025 | Allow | 16 | 2 | 1 | Yes | No |
| 18510460 | ARTICLES OF MANUFACTURE AND METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY | November 2023 | January 2025 | Abandon | 14 | 2 | 0 | No | No |
| 18387555 | XENOTRANSPLANTATION PRODUCTS AND METHODS | November 2023 | June 2025 | Allow | 19 | 1 | 0 | No | No |
| 18382284 | COMPOSITIONS AND METHODS FOR TREATING CANCER | October 2023 | January 2025 | Allow | 15 | 2 | 0 | Yes | No |
| 18480890 | METHOD FOR GENERATING T-CELLS COMPATIBLE FOR ALLOGENIC TRANSPLANTATION | October 2023 | January 2025 | Allow | 15 | 0 | 1 | No | No |
| 18371959 | TAURINE SUPPLEMENTED CELL CULTURE MEDIUM AND METHODS OF USE | September 2023 | July 2024 | Allow | 10 | 2 | 0 | Yes | No |
| 18470861 | Expanding Cells In A Bioreactor | September 2023 | March 2025 | Allow | 18 | 1 | 0 | No | No |
| 18239216 | INJECTABLE HYDROGEL FOR TREATMENT OF SEGMENTAL BONE DEFECT | August 2023 | December 2024 | Allow | 16 | 1 | 1 | No | No |
| 18454288 | Immunosuppressive Antigen-Specific Chimeric Antigen Receptor Treg Cells for Prevention and/or Treatment of Autoimmune and Alloimmune Disorders | August 2023 | August 2024 | Allow | 11 | 0 | 0 | No | No |
| 18447651 | COMPOSITIONS AND METHODS COMPRISING ENGINEERED SHORT NUCLEAR RNA (SNRNA) | August 2023 | February 2024 | Allow | 7 | 0 | 0 | No | No |
| 18361233 | CELL CULTURE MEDIUM | July 2023 | May 2025 | Abandon | 22 | 2 | 0 | Yes | No |
| 18351804 | WET PRESERVATION OF TISSUE | July 2023 | April 2025 | Allow | 21 | 2 | 0 | Yes | No |
| 18351488 | 3-DIMENSIONAL (3D) TISSUE-ENGINEERED MUSCLE FOR TISSUE RESTORATION | July 2023 | April 2025 | Allow | 21 | 1 | 1 | No | No |
| 18347009 | NON-HUMAN ANIMALS COMPRISING A HUMANIZED COAGULATION FACTOR 12 LOCUS | July 2023 | September 2024 | Allow | 14 | 0 | 0 | No | No |
| 18322961 | ONCOLYTIC VIRUSES FOR MODIFIED MHC EXPRESSION | May 2023 | December 2023 | Allow | 7 | 1 | 0 | No | No |
| 18306152 | MICROBEADS FOR CELL CULTURE AND METHOD OF MONITORING CELL CULTURE USING THE SAME | April 2023 | May 2025 | Allow | 25 | 1 | 0 | No | No |
| 18136660 | INDUCIBLE PROMOTERS | April 2023 | April 2025 | Allow | 24 | 1 | 1 | No | No |
| 18191718 | COMPOSITION TO INCREASE CELLULARLONGEVITY | March 2023 | March 2025 | Abandon | 23 | 3 | 1 | No | No |
| 18188326 | T CELL-ANTIGEN COUPLER WITH VARIOUS CONSTRUCT OPTIMIZATIONS | March 2023 | September 2023 | Allow | 6 | 1 | 0 | No | No |
| 18172670 | METHODS FOR INCREASING MANNOSE CONTENT OF RECOMBINANT PROTEINS | February 2023 | October 2023 | Allow | 8 | 1 | 0 | No | No |
| 18166627 | AMNIOTIC CYTOKINE FORMULATIONS | February 2023 | February 2025 | Abandon | 24 | 2 | 0 | No | Yes |
| 18105374 | Oncolytic Immunotherapy by Tumor Micro-Environment Remodeling | February 2023 | May 2025 | Allow | 27 | 4 | 0 | No | No |
| 18156887 | Pocket Engineering of HLA Alleles for Treating Autoimmunity | January 2023 | June 2025 | Allow | 29 | 2 | 1 | Yes | No |
| 18152470 | IN VITRO METHOD FOR CREATING A VIABLE CONNECTIVE TISSUE AND/OR OSSEOUS TISSUE | January 2023 | December 2024 | Allow | 23 | 1 | 0 | No | No |
| 18003067 | THREE-DIMENSIONAL BIOMIMETIC CHIP FOR SIMULATING ENDOMETRIUM, AND ENDOMETRIUM SIMULATING METHOD USING SAME | December 2022 | February 2025 | Allow | 26 | 2 | 0 | No | No |
| 18083019 | Compositions and Manufacture of Allograft Tissue | December 2022 | November 2023 | Allow | 11 | 1 | 1 | Yes | No |
| 18066420 | PSEUDOTYPED VIRAL PARTICLES, COMPOSITIONS COMPRISING THE SAME, AND USES THEREOF | December 2022 | July 2023 | Allow | 7 | 1 | 0 | No | No |
| 18080253 | ONCOLYTIC VIRUSES FOR MODIFIED MHC EXPRESSION | December 2022 | February 2024 | Allow | 14 | 1 | 0 | No | No |
| 18079749 | AAV-Mediated Gene Transfer for Retinopathy | December 2022 | September 2024 | Abandon | 21 | 2 | 0 | Yes | No |
| 18076785 | NOVEL SUPERCOOLING METHODS FOR PRESERVATION OF BIOLOGICAL SAMPLES | December 2022 | September 2024 | Allow | 22 | 1 | 0 | No | No |
| 17779991 | 3D scaffold comprising a biocompatible polymer with a colonization chamber open at the top for biological cells, and with a canal vessel surrounding the colonization chamber | November 2022 | September 2024 | Allow | 28 | 2 | 1 | Yes | No |
| 17988257 | DIFFERENTIATION OF PANCREATIC ENDOCRINE CELLS | November 2022 | September 2023 | Allow | 10 | 1 | 0 | Yes | No |
| 17985587 | METHODS OF PRODUCING T REGULATORY CELLS, METHODS OF TRANSDUCING T CELLS, AND USES OF THE SAME | November 2022 | February 2024 | Abandon | 15 | 0 | 1 | No | No |
| 18052801 | GENE EDITING SYSTEMS COMPRISING AN RNA GUIDE TARGETING HYDROXYACID OXIDASE 1 (HAO1) AND USES THEREOF | November 2022 | September 2023 | Allow | 11 | 1 | 0 | Yes | No |
| 17971623 | Low-macrophage-adhesion/activation culture devices for continuous hematopoiesis and expansion of hematopoietic stem cells and progenitor cells | October 2022 | January 2025 | Abandon | 27 | 1 | 0 | No | No |
| 18047435 | METHOD FOR TREATING ALOPECIA WITH STEM CELL EXOSOME | October 2022 | June 2024 | Abandon | 20 | 1 | 1 | No | No |
| 18046678 | PERSONALIZED CELLS, TISSUES, AND ORGANS FOR TRANSPLANTATION FROM A HUMANIZED, BESPOKE, DESIGNATED-PATHOGEN FREE, (NON-HUMAN) DONOR AND METHODS AND PRODUCTS RELATING TO SAME | October 2022 | December 2024 | Allow | 27 | 1 | 0 | No | No |
| 18046740 | Self-Complementary Adeno-Associated Virus Vector and its Use in Treatment of Muscular Dystrophy | October 2022 | July 2024 | Allow | 21 | 1 | 1 | No | No |
| 17964465 | GENETICALLY MODIFIED NON-HUMAN ANIMALS WITH HUMANIZED IMMUNOGLOBULIN LOCUS | October 2022 | June 2023 | Allow | 8 | 1 | 0 | Yes | No |
| 17935334 | HARVESTING CELL-BASED MEAT | September 2022 | December 2023 | Allow | 15 | 2 | 1 | Yes | No |
| 17945816 | ANTI-LESION STORAGE METHOD AND STORAGE SYSTEM FOR CELLS, TISSUES OR ORGANS | September 2022 | March 2025 | Allow | 30 | 3 | 0 | Yes | No |
| 17930652 | ULTRAPURE MINIVECTORS FOR GENE THERAPY | September 2022 | April 2025 | Abandon | 31 | 1 | 0 | No | No |
| 17930369 | COMBINATIONS OF MRNAS ENCODING IMMUNE MODULATING POLYPEPTIDES AND USES THEREOF | September 2022 | October 2022 | Allow | 2 | 0 | 0 | No | No |
| 17908109 | ENGINEERED IMMUNE CELL AND USE THEREOF | August 2022 | November 2023 | Allow | 14 | 2 | 0 | No | No |
| 17802478 | CELL TREATMENT AGENT | August 2022 | May 2025 | Allow | 33 | 1 | 0 | Yes | No |
| 17895418 | METHOD FOR ISOLATING AND PURIFYING MESENCHYMAL STEM CELLS FROM HERNIA SAC AND METHOD FOR TISSUE REPAIR BY USING MESENCHYMAL STEM CELLS FROM HERNIA SAC | August 2022 | June 2025 | Abandon | 33 | 3 | 1 | Yes | No |
| 17886407 | INDUCTION OF NEUROGENESIS USING UMBILICAL CORD DERIVED MESENCHYMAL STEM CELLS AND DERIVATIVES THEREOF | August 2022 | May 2024 | Abandon | 22 | 0 | 1 | No | No |
| 17819052 | USE OF MESENCHYMAL STEM CELLS AND COMPOSITIONS CONTAINING THEM IN THE MANUFACTURE OF A MEDICAMENT FOR TREATING HARD-TO-HEAL BURN WOUNDS | August 2022 | May 2025 | Abandon | 33 | 3 | 1 | No | No |
| 17818835 | TISSUE-SPECIFICALLY EXPRESSED CIRCULAR RNA MOLECULE AND APPLICATION THEREOF | August 2022 | May 2024 | Abandon | 21 | 1 | 1 | No | No |
| 17883973 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | August 2022 | April 2025 | Allow | 32 | 2 | 0 | No | No |
| 17760333 | MUSCLE-SPECIFIC NUCLEIC ACID REGULATORY ELEMENTS AND METHODS AND USE THEREOF | August 2022 | June 2025 | Allow | 34 | 1 | 1 | No | No |
| 17817051 | WET PRESERVATION OF TISSUE | August 2022 | August 2024 | Allow | 25 | 1 | 0 | No | No |
| 17879746 | METHOD OF LUBRICATING BODILY TISSUE USING AN AMNION DERIVED THERAPEUTIC COMPOSITION | August 2022 | February 2024 | Allow | 18 | 2 | 0 | Yes | No |
| 17813984 | POLYNUCLEOTIDES ENCODING PORPHOBILINOGEN DEAMINASE FOR THE TREATMENT OF ACUTE INTERMITTENT PORPHYRIA | July 2022 | March 2025 | Allow | 32 | 1 | 0 | No | No |
| 17870569 | METHOD FOR PRODUCING RETINAL TISSUE AND RETINA-RELATED CELLS | July 2022 | April 2025 | Allow | 32 | 1 | 0 | No | No |
| 17867128 | METHODS AND MEANS FOR INDUCING AN IMMUNE RESPONSE | July 2022 | February 2025 | Abandon | 31 | 1 | 0 | No | No |
| 17862721 | METHODS FOR ENHANCING EFFICACY OF THERAPEUTIC IMMUNE CELLS | July 2022 | February 2023 | Allow | 7 | 2 | 0 | Yes | No |
| 17861914 | Methods Of HLA Engineering and Treatments For Autoimmunity | July 2022 | December 2023 | Abandon | 18 | 1 | 1 | No | No |
| 17859564 | THERAPEUTIC AGENTS COMPRISING ONCOLYTIC VACCINIA VIRUSES AND NK CELLS, AND USES THEREOF FOR DRUGS FOR TREATMENT OF TUMORS AND/OR CANCERS | July 2022 | September 2024 | Abandon | 27 | 1 | 0 | No | No |
| 17859470 | DELIVERY OF GENE THERAPY TREATMENTS | July 2022 | March 2025 | Allow | 33 | 1 | 0 | No | No |
| 17858869 | TREATMENT OF PARKINSON'S DISEASE BY IMMUNE MODULATION AND REGENERATIVE MEANS | July 2022 | January 2024 | Abandon | 19 | 1 | 0 | No | No |
| 17850882 | CELL PREPARATION METHOD, CELL CULTIVATION DEVICE, AND KIT | June 2022 | January 2025 | Abandon | 31 | 1 | 0 | No | No |
| 17846868 | ARTICLES OF MANUFACTURE AND METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY | June 2022 | August 2023 | Allow | 13 | 1 | 0 | Yes | No |
| 17845660 | ANELLOVIRUS COMPOSITIONS AND METHODS OF USE | June 2022 | February 2025 | Allow | 32 | 2 | 0 | No | No |
| 17842639 | ADENO-ASSOCIATED VIRUS VIRIONS WITH VARIANT CAPSID AND METHODS OF USE THEREOF | June 2022 | September 2022 | Allow | 3 | 0 | 0 | Yes | No |
| 17842553 | ADENO-ASSOCIATED VIRUS VIRIONS WITH VARIANT CAPSID AND METHODS OF USE THEREOF | June 2022 | September 2022 | Allow | 3 | 0 | 0 | Yes | No |
| 17830425 | METHODS OF TREATING ACUTE RESPIRATORY DISTRESS SYNDROME | June 2022 | August 2024 | Abandon | 26 | 1 | 0 | No | No |
| 17827934 | BIOENERGETIC BONE | May 2022 | May 2025 | Allow | 35 | 2 | 0 | Yes | No |
| 17750855 | CONSTRUCTION OF CHIMERIC ANTIGEN RECEPTOR TARGETING CD20 ANTIGEN AND ACTIVITY IDENTIFICATION OF ENGINEERED T CELLS THEREOF | May 2022 | November 2022 | Allow | 6 | 1 | 0 | No | No |
| 17751266 | CHIMERIC ANTIGEN RECEPTOR | May 2022 | February 2025 | Allow | 33 | 3 | 1 | Yes | No |
| 17664194 | CELL CRYOPRESERVATION COMPOSITION AND CRYOPRESERVATION METHOD | May 2022 | June 2024 | Allow | 25 | 0 | 0 | No | No |
| 17746664 | COMPOSITIONS AND METHODS COMPRISING ENGINEERED CHIMERIC ANTIGEN RECEPTOR AND MODULATOR OF CAR | May 2022 | December 2024 | Allow | 31 | 0 | 0 | Yes | No |
| 17662766 | COMPOSITIONS AND METHODS FOR TREATING MESOTHELIN POSITIVE CANCERS | May 2022 | October 2022 | Allow | 5 | 0 | 0 | No | No |
| 17741438 | HLA ENGINEERING METHODS AND COMPOSITIONS FOR TREATMENT OF AUTOIMMUNITY | May 2022 | December 2024 | Allow | 31 | 1 | 1 | No | No |
| 17740045 | CODON OPTIMIZED REP1 GENES AND USES THEREOF | May 2022 | August 2022 | Allow | 3 | 1 | 0 | No | No |
| 17774968 | ISOLATION, PRESERVATION, AND EXPANSION OF CANINE UMBILICAL CORD MESENCHYMAL STROMAL CELLS | May 2022 | June 2025 | Allow | 37 | 1 | 1 | No | No |
| 17736953 | PROCESSES FOR GENERATING TIL PRODUCTS ENRICHED FOR TUMOR ANTIGEN-SPECIFIC T-CELLS | May 2022 | March 2023 | Allow | 11 | 1 | 0 | No | No |
| 17736579 | DEVICES AND METHODS FOR DELIVERING THERAPEUTICS | May 2022 | August 2024 | Allow | 28 | 1 | 0 | Yes | No |
| 17733875 | DEVICES AND METHODS FOR ISOLATING TUMOR INFILTRATING LYMPHOCYTES AND USES THEREOF | April 2022 | January 2023 | Allow | 8 | 1 | 0 | No | No |
| 17732234 | METHODS FOR PRODUCING CELL POPULATIONS WITH INCREASED NUCLEIC ACID UPTAKE | April 2022 | October 2023 | Abandon | 17 | 1 | 1 | No | No |
| 17731748 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | April 2022 | October 2022 | Allow | 5 | 0 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1633.
With a 28.3% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 12.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Art Unit 1633 is part of Group 1630 in Technology Center 1600. This art unit has examined 11,564 patent applications in our dataset, with an overall allowance rate of 44.8%. Applications typically reach final disposition in approximately 38 months.
Art Unit 1633's allowance rate of 44.8% places it in the 4% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.
Applications in Art Unit 1633 receive an average of 2.38 office actions before reaching final disposition (in the 87% percentile). The median prosecution time is 38 months (in the 10% percentile).
When prosecuting applications in this art unit, consider the following:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.